GÖTTINGEN, Germany,
Dec. 16, 2021 /PRNewswire/ -- The
life science group Sartorius is expanding its bioanalytics
portfolio by acquiring a majority stake in ALS Automated Lab
Solutions GmbH. The laboratory technology company based in Jena,
Germany, develops, manufactures
and markets solutions for the automated analysis, selection and
isolation of cells. With these solutions, ALS enables life science
customers to significantly reduce time to result and cost in cell
line development and antibody discovery. Other application areas
are the development of cell and gene therapeutics as well as rare
single cell molecular diagnostics in cancer and prenatal
research.
Sartorius is initially purchasing 62.5 percent of the
shares in ALS as of January 3, 2022. The remaining
37.5 percent will be acquired in 2026. ALS currently employs
around 30 people and is expected to generate sales in the high
single-digit million-euro area in 2021, with a double-digit EBITDA
margin.
"We are helping our customers to increase their overall R&D
efficiency. By doing so, we are contributing toward getting
medicines faster to the market. With the acquisition of a majority
stake in ALS, we are extending our offer in the field of
bioanalytics by another complementary technology, further
broadening our position in life science research. As a result, we
are also strengthening our access to customers in very early stages
of drug development," said Gerry
Mackay, member of the Executive Board and Head of the Lab
Products & Services Division of Sartorius.
"We are delighted to join the Sartorius family. There is strong
interest in our products and solutions from life science customers
all over the world. This transaction will further enhance
regulatory expertise as well as access to local support. Both are
important factors for our customers," said Jens Eberhardt, CEO and co-founder of ALS.
"The combination with Sartorius will enable ALS to speed up new
developments and to complement our existing product portfolio with
additional consumables, reagent kits and protocols. This is a
fundamental step in our journey from a manufacturer of laboratory
systems to a provider of complete end-to-end solutions," said
Gerd Bornmann, CEO and co-founder of
ALS.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
About ALS
ALS Automated Lab Solutions develops, manufactures and sells
high-quality automated solutions for life sciences in a broad range
of areas including molecular diagnostics, cancer and stem cell
research, cell line development and bioprocessing. The company's
core competencies are in automated cell manipulation, cell sorting
and isolation, microscopic high-content imaging and analysis as
well as liquid handling. The ALS CellCelector™ is the
world's leading single cell and colony picking platform and is
based on a multi-patented, unique cell and colony isolation
technology which provides unmatched flexibility, high-quality
results, operational reliability, cost-effectiveness and simple
use. ALS Automated Lab Solutions GmbH is headquartered in Jena,
Germany.
Contact
Philipp Grontzki
Head of External Communications
+49 (0)551.308.5581
philipp.grontzki@sartorius.com
www.sartorius.com/en
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sartorius-strengthens-its-bioanalytics-portfolio-by-acquiring-a-majority-stake-in-als-automated-lab-solutions-301446357.html
SOURCE Sartorius AG
